Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.
Lejeune F, Chatton A, Laplaud DA, Le Page E, Wiertlewski S, Edan G, Kerbrat A, Veillard D, Hamonic S, Jousset N, Le Frère F, Ouallet JC, Brochet B, Ruet A, Foucher Y, Michel L. Lejeune F, et al. Among authors: laplaud da. J Neurol. 2021 Feb;268(2):669-679. doi: 10.1007/s00415-020-10154-5. Epub 2020 Sep 9. J Neurol. 2021. PMID: 32902734
[Adaptative immunity and pathophysiology of multiple sclerosis].
Salou M, Elong Ngono A, Garcia A, Michel L, Laplaud DA. Salou M, et al. Among authors: laplaud da. Rev Med Interne. 2013 Aug;34(8):479-86. doi: 10.1016/j.revmed.2013.03.327. Epub 2013 Apr 24. Rev Med Interne. 2013. PMID: 23622732 Review. French.
Unique B cell differentiation profile in tolerant kidney transplant patients.
Chesneau M, Pallier A, Braza F, Lacombe G, Le Gallou S, Baron D, Giral M, Danger R, Guerif P, Aubert-Wastiaux H, Néel A, Michel L, Laplaud DA, Degauque N, Soulillou JP, Tarte K, Brouard S. Chesneau M, et al. Among authors: laplaud da. Am J Transplant. 2014 Jan;14(1):144-55. doi: 10.1111/ajt.12508. Epub 2013 Nov 13. Am J Transplant. 2014. PMID: 24354874 Free article.
Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients.
Le Berre L, Rousse J, Gourraud PA, Imbert-Marcille BM, Salama A, Evanno G, Semana G, Nicot A, Dugast E, Guérif P, Adjaoud C, Freour T, Brouard S, Agbalika F, Marignier R, Brassat D, Laplaud DA, Drouet E, Van Pesch V, Soulillou JP. Le Berre L, et al. Among authors: laplaud da. Clin Immunol. 2017 Jul;180:128-135. doi: 10.1016/j.clim.2017.05.006. Epub 2017 May 18. Clin Immunol. 2017. PMID: 28506921 Free article.
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Michel L, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: laplaud da. Mult Scler. 2025 Jan;31(1):69-80. doi: 10.1177/13524585241289276. Epub 2024 Dec 1. Mult Scler. 2025. PMID: 39618051
Association between education level and disability progression in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Le Page E, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: laplaud da. Mult Scler. 2025 Jan;31(1):59-68. doi: 10.1177/13524585241289274. Epub 2024 Nov 30. Mult Scler. 2025. PMID: 39614776
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Sèze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frénay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zéphir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanché JP, Doghri I, Wahab A, Tchikviladzé M, Labeyrie C, Hankiewicz K, Le Page E, Michel L; as the OFSEP Investigators. Hay M, et al. Among authors: laplaud da. Neurology. 2024 Oct 22;103(8):e209886. doi: 10.1212/WNL.0000000000209886. Epub 2024 Sep 25. Neurology. 2024. PMID: 39321406
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
108 results